Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients eligible for Hepatit Transplantation | Other | Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged. HT takes place according to transplant availability. As soon as the patient is able to return home after HT, a visit is organised, defining the T1 period. A visit is carried out 120 days after HT and the end-of-study visit is scheduled to define the T2 period, which is the same length as the T1 period for each patient. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| a blood test and urine sample collection. | Other | The study is offered to all patients who meet the inclusion criteria during their pre-transplant assessment by the principal investigator (during an existing visit). Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged. |
| Measure | Description | Time Frame |
|---|---|---|
| hepatic transplantation reduces arterial calcification | compare the percent of patients with AC progression before and after liver tranplantation | On the 7th day after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| identify arterial calcification related factors | separation of patients according to AC progression (yes or no) and machine learning analysis with all relevant factors | On the 7th day after surgery |
| increase of PPi plasma level after liver transplantation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Guillaume FAVRE, PhD | Contact | +33492039220 | favre.g@chu-nice.fr | |
| Gullaume Marrane | Contact | +33492039220 | marrane.g@chu-nice.fr |
| Name | Affiliation | Role |
|---|---|---|
| Guillaume FAVRE, PhD | CRC, Néphrologie - CHU de Nice - Hôpital de l'Archet | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nice | Recruiting | Nice | Alpes-maritimes | 06200 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008103 | Liver Cirrhosis |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
comparison of mean plasma levels before and after |
| at inclusion and at 3 months |
| D013568 |
| Pathological Conditions, Signs and Symptoms |